鲁索利替尼作为慢性移植物抗宿主病补救性治疗的长期随访结果

IF 1.8 Q3 HEMATOLOGY
Neslihan Mandaci Sanli , Esen Karakuş
{"title":"鲁索利替尼作为慢性移植物抗宿主病补救性治疗的长期随访结果","authors":"Neslihan Mandaci Sanli ,&nbsp;Esen Karakuş","doi":"10.1016/j.htct.2025.103835","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Chronic graft-versus-host disease poses a significant challenge after allogeneic hematopoietic stem cell transplantation with initial treatment often relying on high-dose steroids. However, managing steroid-refractory disease remains daunting. Recent insights into the mechanisms have unveiled new treatment targets, with ruxolitinib, a selective JAK1/2 inhibitor, emerging as a promising and safe therapy for chronic graft-versus-host disease patients.</div></div><div><h3>Methods</h3><div>This retrospective study describes the long-term outcomes of 23 chronic graft-versus-host disease patients treated with ruxolitinib.</div></div><div><h3>Results</h3><div>Most patients presented with severe chronic graft-versus-host disease (15/23; 65.2%). The overall response rate was 78.3% (18/23) after a median treatment duration of four weeks, with 55.6% (10/18) achieving complete response. At follow-up, 13 of the 18 responders (72.2%) sustained complete remission. Patients had a median of two previous lines of therapy, with a median follow-up of 14 months (range: 2–46 months) after starting ruxolitinib. Of the patients who were responsive to ruxolitinib, median follow-up extended to 26.5 months. Notably, for the patients who were responsive to ruxolitinib, the 1-year, 2-year, and 3-year overall survival was 83.3% (95% CI: 64.2%-102%), 56.1% (95% CI: 30.1%-80.9%), and 33.3% (95% CI: 9.2%-57.4%), respectively. Malignancy relapse occurred in 17.4% (4/23) of patients, with 34.7% (8/23) experiencing cytopenias, albeit mostly mild. Reactivation rates for cytomegalovirus were nil.</div></div><div><h3>Conclusion</h3><div>The long-term follow-up in this study supports ruxolitinib as an effective salvage therapy for chronic graft-versus-host disease with a 78.3% overall response rate and 55.6% complete remission rate. However, large prospective studies are warranted to validate these findings</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 3","pages":"Article 103835"},"PeriodicalIF":1.8000,"publicationDate":"2025-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-term follow-up results of ruxolitinib as salvage therapy for chronic graft-versus-host disease\",\"authors\":\"Neslihan Mandaci Sanli ,&nbsp;Esen Karakuş\",\"doi\":\"10.1016/j.htct.2025.103835\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>Chronic graft-versus-host disease poses a significant challenge after allogeneic hematopoietic stem cell transplantation with initial treatment often relying on high-dose steroids. However, managing steroid-refractory disease remains daunting. Recent insights into the mechanisms have unveiled new treatment targets, with ruxolitinib, a selective JAK1/2 inhibitor, emerging as a promising and safe therapy for chronic graft-versus-host disease patients.</div></div><div><h3>Methods</h3><div>This retrospective study describes the long-term outcomes of 23 chronic graft-versus-host disease patients treated with ruxolitinib.</div></div><div><h3>Results</h3><div>Most patients presented with severe chronic graft-versus-host disease (15/23; 65.2%). The overall response rate was 78.3% (18/23) after a median treatment duration of four weeks, with 55.6% (10/18) achieving complete response. At follow-up, 13 of the 18 responders (72.2%) sustained complete remission. Patients had a median of two previous lines of therapy, with a median follow-up of 14 months (range: 2–46 months) after starting ruxolitinib. Of the patients who were responsive to ruxolitinib, median follow-up extended to 26.5 months. Notably, for the patients who were responsive to ruxolitinib, the 1-year, 2-year, and 3-year overall survival was 83.3% (95% CI: 64.2%-102%), 56.1% (95% CI: 30.1%-80.9%), and 33.3% (95% CI: 9.2%-57.4%), respectively. Malignancy relapse occurred in 17.4% (4/23) of patients, with 34.7% (8/23) experiencing cytopenias, albeit mostly mild. Reactivation rates for cytomegalovirus were nil.</div></div><div><h3>Conclusion</h3><div>The long-term follow-up in this study supports ruxolitinib as an effective salvage therapy for chronic graft-versus-host disease with a 78.3% overall response rate and 55.6% complete remission rate. However, large prospective studies are warranted to validate these findings</div></div>\",\"PeriodicalId\":12958,\"journal\":{\"name\":\"Hematology, Transfusion and Cell Therapy\",\"volume\":\"47 3\",\"pages\":\"Article 103835\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-05-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematology, Transfusion and Cell Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2531137925001038\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology, Transfusion and Cell Therapy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2531137925001038","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

慢性移植物抗宿主病是同种异体造血干细胞移植后的一个重大挑战,初始治疗通常依赖于大剂量类固醇。然而,管理类固醇难治性疾病仍然令人望而生畏。最近对其机制的深入研究揭示了新的治疗靶点,选择性JAK1/2抑制剂ruxolitinib成为慢性移植物抗宿主病患者的一种有前景且安全的治疗方法。方法本回顾性研究描述了23例慢性移植物抗宿主病患者接受鲁索利替尼治疗的长期结果。结果大多数患者表现为严重的慢性移植物抗宿主病(15/23;65.2%)。中位治疗时间4周后,总缓解率为78.3%(18/23),55.6%(10/18)达到完全缓解。在随访中,18名应答者中有13名(72.2%)持续完全缓解。患者在开始使用ruxolitinib后,中位随访时间为14个月(范围:2-46个月)。对鲁索利替尼有反应的患者,中位随访延长至26.5个月。值得注意的是,对于对鲁索利替尼有反应的患者,1年、2年和3年的总生存率分别为83.3% (95% CI: 64.2%-102%)、56.1% (95% CI: 30.1%-80.9%)和33.3% (95% CI: 9.2%-57.4%)。17.4%(4/23)的患者出现恶性复发,34.7%(8/23)的患者出现细胞减少,但大多是轻微的。巨细胞病毒的再激活率为零。结论本研究的长期随访支持ruxolitinib作为慢性移植物抗宿主病的有效补救性治疗,总有效率为78.3%,完全缓解率为55.6%。然而,有必要进行大规模的前瞻性研究来验证这些发现
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Long-term follow-up results of ruxolitinib as salvage therapy for chronic graft-versus-host disease

Introduction

Chronic graft-versus-host disease poses a significant challenge after allogeneic hematopoietic stem cell transplantation with initial treatment often relying on high-dose steroids. However, managing steroid-refractory disease remains daunting. Recent insights into the mechanisms have unveiled new treatment targets, with ruxolitinib, a selective JAK1/2 inhibitor, emerging as a promising and safe therapy for chronic graft-versus-host disease patients.

Methods

This retrospective study describes the long-term outcomes of 23 chronic graft-versus-host disease patients treated with ruxolitinib.

Results

Most patients presented with severe chronic graft-versus-host disease (15/23; 65.2%). The overall response rate was 78.3% (18/23) after a median treatment duration of four weeks, with 55.6% (10/18) achieving complete response. At follow-up, 13 of the 18 responders (72.2%) sustained complete remission. Patients had a median of two previous lines of therapy, with a median follow-up of 14 months (range: 2–46 months) after starting ruxolitinib. Of the patients who were responsive to ruxolitinib, median follow-up extended to 26.5 months. Notably, for the patients who were responsive to ruxolitinib, the 1-year, 2-year, and 3-year overall survival was 83.3% (95% CI: 64.2%-102%), 56.1% (95% CI: 30.1%-80.9%), and 33.3% (95% CI: 9.2%-57.4%), respectively. Malignancy relapse occurred in 17.4% (4/23) of patients, with 34.7% (8/23) experiencing cytopenias, albeit mostly mild. Reactivation rates for cytomegalovirus were nil.

Conclusion

The long-term follow-up in this study supports ruxolitinib as an effective salvage therapy for chronic graft-versus-host disease with a 78.3% overall response rate and 55.6% complete remission rate. However, large prospective studies are warranted to validate these findings
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.40
自引率
4.80%
发文量
1419
审稿时长
30 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信